Novo Nordisk's biggest revenue contributor in the third quarter, Simeglutide, made its debut at the CIIE
王俊杰2017
发表于 6 小时前
113
0
0
Novo Nordisk's third quarter report once again shows the industry the market potential of the star product Smeaglutide. On November 6th, Novo Nordisk released its third quarter report showing a year-on-year revenue growth of 23%, with the largest growth driven by semaglutide, accounting for 69% of Novo Nordisk's revenue. At the same time as the global release of its third quarter report, Novo Nordisk is showcasing its major product, semaglutide, at the CIIE. The first exhibition in China includes the world's first and currently only GLP-1 receptor agonist, semaglutide tablets (trade name: Novozymes), and the world's first GLP-1 weekly formulation for long-term weight management, Novozymes, also known as semaglutide injection for long-term weight management.
Zhou Xiaping, Senior Vice President of Novo Nordisk Global and President of Greater China, stated that Novo Nordisk has been continuously leading the research and development breakthroughs of GLP-1 drugs. At this CIIE, Novo Nordisk launched the "Healthy China Action - Metabolic Renewal Year" campaign. Through the CIIE platform, Novo Nordisk has witnessed numerous innovative drugs accelerating their landing in China and even obtaining approval simultaneously, completing the transformation from "exhibits" to "commodities", and also achieving pioneering innovation in public science education.
In addition, in terms of financial reports, in a single quarter, Novo Nordisk's third quarter revenue was 71.311 billion Danish kroner, a year-on-year increase of 22%, and net profit was 27.301 billion Danish kroner, a year-on-year increase of 21%, higher than market expectations. Affected by the above news, Novo Nordisk rose by over 6% before the stock market opened on November 6th. Overall, in the first three quarters, Novo Nordisk's revenue was KRK 204.72 billion, a year-on-year increase of 23%; Net profit was 72.758 billion Danish kroner, an increase of 18% year-on-year.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Microsoft's first quarter revenue exceeded expectations
- Revenue and profit both decline, who is eating Nike's market
- Intel falls, AMD eats its fill! Wall Street predicts a significant decline in Intel's Q3 revenue
- Q4 revenue guidance falls short of expectations, Ideal US stock drops by over 13%, Li Xiang can still receive over 600 million yuan in equity incentives
- Establishing a green channel for high-quality brands, Vipshop is seeking gold at the Shanghai International Import Expo
- 2024 CIIE | Abbott's dual chamber wireless cardiac pacemaker makes global debut
- Ericsson China President Fang Ying: CIIE provides a shared innovation platform for global enterprises
- Dingdong Maicai's "Buyer Team" plans to "Buy Global" at the China International Import Expo, with purchase orders reaching over 100 million yuan
- Novartis' kidney product portfolio makes its debut at the China International Import Expo, and the company stated that it will actively promote the product's launch
- 2024 Enter the Expo | Improve local innovation ability, Nike digs gold in China's running market
-
ファイザーが前立腺がんを治療する革新薬テゼナ& ;reg;(TALZENNA®,一般名:トルエンスルホン酸タラゾールパーリカプセル)は2024年10月29日に国家薬品監督管理局(NMPA)の承認を得て、HRR遺伝子突然変異 ...
- 什么大师特
- 前天 17:41
- 支持
- 反对
- 回复
- 收藏
-
南方財経は11月5日、中央テレビのニュースによると、現地時間11月5日、米ボーイング社のストライキ労働者が59%の投票結果で新たな賃金協定を受け入れ、7週間にわたるストライキを終えた。ストライキ労働者は11月12 ...
- Dubssgshbsbdhd
- 前天 16:27
- 支持
- 反对
- 回复
- 收藏
-
【マスクはテスラが携帯電話を作ることに応えた:作れるが作らないアップルとグーグルが悪さをしない限り】現地時間11月5日、有名ポッドキャストのジョローガン氏のインタビューに応じ、「携帯電話を作るのは私たち ...
- 波大老师
- 前天 14:41
- 支持
- 反对
- 回复
- 收藏
-
自動車企業のStellantisグループは現地時間11月6日、米オハイオ州トレドのJeep工場で過剰在庫を消化するために約1100人を削減すると発表した。同社はJeep Gladiatorピックアップを生産するToledo South工場を2班制 ...
- 什么大师特
- 10 小时前
- 支持
- 反对
- 回复
- 收藏